BioCentury
ARTICLE | Company News

GlycoDesign, Seikagaku Corp. deal

February 10, 2003 8:00 AM UTC

GD regained IP and marketing rights from Seikagaku to Core 2 transferase inhibitors under the companies' 1999 research collaboration. GD said it will develop the compounds internally for anti-inflammatory conditions. ...